CER Daily Newsfeed

Enhancing Healthcare Decision-Making: Leveraging Data-Driven Value Analysis for Better Outcomes

(11/26, ECRI Blog) comments “...In healthcare, the decisions made during the value analysis process can significantly impact patient outcomes and operational efficiency. To make these decisions count, it's essential to rely on accurate, relevant data that spans clinical evidence, safety, financial impact, and market factors. By systematically gathering and analyzing this information, healthcare professionals can ensure that their choices are both effective and aligned with broader strategic goals.” Full

Minnesota Becomes First State to Release Report on 340B Drug Discount Program for 'Safety-Net' Hospitals

(11/25, Ed Silverman, STAT Plus) reports “...Specifically, [Minnesota] hospitals received $1.5 billion in discounted medicines under the 340B Drug Discount program, but paid $734 million plus another $120 million to various parties for administration fees. Meanwhile, the largest hospitals received roughly $500 million, representing 80% of the total revenue collected. Yet these institutions accounted for only 13% of the total number of participating hospitals. The report is the first ever compiled by a state in response to controversy over the 340B program.” Subscription Required

UK MHRA Calls On Pharma To Embrace RWD Early

(11/26, Anabel Costa-Ferreira, Pink Sheet) reports “...The UK Medicines and Healthcare products Regulatory Agency (MHRA) is encouraging companies to ‘spread the word, have ideas and come talk’ about their real-world evidence (RWE) strategies, with the aim of moving these discussions to earlier stages of the drug development cycle.” Subscription Required

Navigating The Uncharted Waters Of EU HTA

(11/26, Alexander Natz and Matias Olsen, Pink Sheet) reports “...The EU-level joint clinical assessments that will be introduced under the Health Technology Assessment Regulation from January 2025 represent a huge shift for drug companies launching products in the EU. Industry experts Alexander Natz and Matias Olsen offer key advice to help companies prepare for what is to come.” Subscription Required

EU HTA Regulation A Positive Move For Rare Disease Therapies, says EURORDIS Chief

(11/26, Eliza Slawther, Pink Sheet) reports “...Greater transparency around EU health technology assessment processes ‘can only be a good thing’ for innovative rare disease therapies, Virginie Bros-Facer, the new CEO of the EU network of rare disease patient organizations, EURORDIS, tells the Pink Sheet.” Subscription Required